Medpace is a diagnostics & research business based in the US. Medpace shares (MEDP) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $326.09 – a decrease of 2.61% over the previous week. Medpace employs 5,900 staff and has a trailing 12-month revenue of around $2.1 billion.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $326.09 |
|---|---|
| 52-week range | $268.80 - $459.77 |
| 50-day moving average | $342.27 |
| 200-day moving average | $378.49 |
| Wall St. target price | $349.32 |
| PE ratio | 29.3205 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $11.42 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $314.96 from 2024-11-19
| 1 week (2024-11-14) | -5.94% |
|---|---|
| 1 month (2024-10-21) | -10.76% |
| 3 months (2024-08-20) | -19.11% |
| 6 months (2024-05-20) | -20.71% |
| 1 year (2023-11-21) | 14.00% |
|---|---|
| 2 years (2022-11-21) | 43.88% |
| 3 years (2021-11-19) | 38.74% |
| 5 years (2019-11-21) | 321.41% |
Valuing Medpace stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Medpace's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Medpace's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 29x. In other words, Medpace shares trade at around 29x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Medpace's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.5928. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Medpace's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Medpace's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $437.5 million.
The EBITDA is a measure of a Medpace's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $2.1 billion |
|---|---|
| Operating margin TTM | 21.05% |
| Gross profit TTM | $925.1 million |
| Return on assets TTM | 14.31% |
| Return on equity TTM | 54.08% |
| Profit margin | 17.66% |
| Book value | $28.42 |
| Market Capitalization | $10.4 billion |
TTM: trailing 12 months
We're not expecting Medpace to pay a dividend over the next 12 months.
Over the last 12 months, Medpace's shares have ranged in value from as little as $268.795 up to $459.77. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Medpace's is 1.367. This would suggest that Medpace's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.